Novel approaches in fighting herpes simplex virus infections

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 5, 2009, Pages 559-568

  Wilson, Sarah S ^a   Fakioglu, Esra ^a   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acyclovir; Herpes simplex virus; Microbicide; Vaccine

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BAY 57 1293; CIDOFOVIR; ENZYME INHIBITOR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; GUANOSINE DERIVATIVE; HELICASE INHIBITOR; HERPES SIMPLEX VACCINE; HYDROCORTISONE; IMIQUIMOD; INTERFERON; LIVE VACCINE; ME 609; MICROBICIDE; NUCLEOSIDE ANALOG; PENCICLOVIR; POLYINOSINIC POLYCYTIDYLIC ACID; PRIMASE INHIBITOR; PROBENECID; RESIQUIMOD; SUBUNIT VACCINE; TOLL LIKE RECEPTOR AGONIST; TRIFLURIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VIDARABINE; ANTIINFECTIVE AGENT; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ENCEPHALITIS; ERADICATION THERAPY; GENITAL HERPES; GENITAL ULCER; GINGIVOSTOMATITIS; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; KERATITIS; NEPHROTOXICITY; NEWBORN INFECTION; NONHUMAN; PUBLIC HEALTH; REVIEW; STOMATITIS; UNSPECIFIED SIDE EFFECT; VIRUS ENCEPHALITIS; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS SHEDDING; VIRUS TRANSMISSION; DISEASE TRANSMISSION; FEMALE; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX KERATITIS; MALE; NEWBORN; PREGNANCY; SYNDROME;

ACYCLOVIR; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; ENCEPHALITIS, HERPES SIMPLEX; FEMALE; HERPES GENITALIS; HERPES SIMPLEX; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; KERATITIS, HERPETIC; MALE; PREGNANCY; STOMATITIS, HERPETIC; SYNDROME; VIRAL VACCINES;

EID: 68249137329     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.34     Document Type: Review

References (90)

1. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl Acad. Sci. USA 74(12), 5716-5720 (1977).
2. Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J. Biol. Chem. 253(24), 8721-8727 (1978).
3. Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ 314(7097), 1800-1803 (1997).
4. Evans TG, Bernstein DI, Raborn GW, Harmenberg J, Kowalski J, Spruance SL. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiationinduced herpes labialis. Antimicrob. Agents Chemother. 46(6), 1870-1874 (2002).
5. Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch. Ophthalmol. 121(1), 108-112 (2003).
6. Wilhelmus KR. Therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst. Rev. 1, CD002898 (2008).
7. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Herpetic Eye Disease Study Group. Arch. Ophthalmol. 118(8), 1030-1036 (2000).
8. Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res. 71(2-3), 141-148 (2006).
9. Casrouge A, Zhang SY, Eidenschenk C et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314(5797), 308-312 (2006). (Pubitemid 44571977)
10. Zhang SY, Jouanguy E, Ugolini S et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317(5844), 1522-1527 (2007). (Pubitemid 47417427)
11. Xu F, Sternberg MR, Kottiri BJ et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296(8), 964-973 (2006). (Pubitemid 44285373)
12. Nagot N, Ouedraogo A, Foulongne V et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N. Engl. J. Med. 356(8), 790-799 (2007). (Pubitemid 46294611)
13. Corey L, Wald A, Patel R et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 350(1), 11-20 (2004). • Demonstrates that once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, herpes simplex virus (HSV)-2-discordant couples. (Pubitemid 38032179)
14. Wald A, Selke S, Warren T et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex. Transm. Dis. 33(9), 529-533 (2006). (Pubitemid 44318975)
15. Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst. Rev. 1, CD004946 (2008).
16. Abu-Raddad LJ, Magaret AS, Celum C et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3(5), e2230 (2008).
17. Biswas S, Tiley LS, Zimmermann H, Birkmann A, Field HJ. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity. Antiviral Res. 80(1), 81-85 (2008).
18. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20(1), 73-83 (2006).
19. Zuckerman RA, Lucchetti A, Whittington WL et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J. Infect. Dis. 196(10), 1500-1508 (2007).
20. Zuckerman RA, Lucchetti A, Whittington WL et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/ HSV-2 co-infected men who have sex with men. AIDS 23(4), 479-483 (2009).
21. Watson-Jones D, Weiss HA, Rusizoka M et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N. Engl. J. Med. 358(15), 1560-1571 (2008). • Representative of clinical trials demonstrating that suppression of HSV with acyclovir may reduce HIV infection.
22. Fakioglu E, Wilson SS, Mesquita PM et al. Herpes simplex virus down-regulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J. Virol. 82(19), 9337-9344 (2008).
23. Van de Perre P, Segondy M, Foulongne V et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect. Dis. 8(8), 490-497 (2008). (Pubitemid 352005823)
24. Lisco A, Vanpouille C, Tchesnokov EP et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 4(3), 260-270 (2008). • Demonstrates that phosphorylated acyclovir inhibits HIV and suggests that acyclovir may have efficacy in the setting of dual infection with both pathogens.
25. McMahon MA, Siliciano JD, Lai J et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J. Biol. Chem. 283(46), 31289-31293 (2008).
26. Kimberlin DW, Lin CY, Jacobs RF et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 108(2), 223-229 (2001).
27. Whitley R, Arvin A, Prober C et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N. Engl. J. Med. 324(7), 444-449 (1991).
28. Kimberlin DW, Lin CY, Jacobs RF et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 108(2), 230-238 (2001).
29. Whitley R, Arvin A, Prober C et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N. Engl. J. Med. 324(7), 450-454 (1991).
30. Kimberlin D, Powell D, Gruber W et al. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a Phase I/II trial. Pediatr. Infect. Dis. J. 15(3), 247-254 (1996). (Pubitemid 26098476)
31. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 76(5), 369-380 (1997).
32. Feinberg JE, Hurwitz S, Cooper D et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J. Infect. Dis. 177(1), 48-56 (1998).
33. DeJesus E, Wald A, Warren T et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J. Infect. Dis. 188(7), 1009-1016 (2003). (Pubitemid 37268251)
34. Reyes M, Shaik NS, Graber JM et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch. Intern. Med. 163(1), 76-80 (2003). (Pubitemid 36091604)
35. Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J. Infect. Dis. 198(5), 659-663 (2008).
36. Frobert E, Cortay JC, Ooka T et al. Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACV-sensitive and 14 ACV-resistant viruses. Antiviral Res. 79(1), 28-36 (2008).
37. Balzarini J, Naesens L, De Clercq E. New antivirals - mechanism of action and resistance development. Curr. Opin. Microbiol. 1(5), 535-546 (1998). (Pubitemid 128433641)
38. Kleymann G, Fischer R, Betz UA et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 8(4), 392-398 (2002). (Pubitemid 34407035)
39. Betz UA, Fischer R, Kleymann G, Hendrix M, Rubsamen-Waigmann H. Potent In vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother. 46(6), 1766-1772 (2002). (Pubitemid 34535195)
40. Biswas S, Jennens L, Field HJ. The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res. 75(1), 30-35 (2007). (Pubitemid 46621066)
41. Baumeister J, Fischer R, Eckenberg P, Henninger K, Ruebsamen-Waigmann H, Kleymann G. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir. Chem. Chemother. 18(1), 35-48 (2007). (Pubitemid 46426936)
42. Kaufman HE, Varnell ED, Gebhardt BM et al. Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection. J. Ocul. Pharmacol. Ther. 24(1), 34-42 (2008).
43. Biswas S, Field HJ. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations. Antivir. Chem. Chemother. 19(1), 1-6 (2008).
44. Biswas S, Smith C, Field HJ. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1. J. Antimicrob. Chemother. 60(2), 274-279 (2007). (Pubitemid 46426934)
45. Boivin N, Sergerie Y, Rivest S, Boivin G. Effect of pretreatment with Toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis. J. Infect. Dis. 198(5), 664-672 (2008).
46. Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J. Infect. Dis. 190(10), 1841-1849 (2004).
47. Mark KE, Corey L, Meng TC et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis. 195(9), 1324-1331 (2007). (Pubitemid 46649619)
48. Weitgasser H. [Controlled clinical study of the herpes antigens LUPIDON H and LUPIDON G]. Z. Hautkr. 52(11), 625-628 (1977).
49. Skinner GR, Turyk ME, Benson CA et al. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. Med. Microbiol. Immunol. 186(1), 31-36 (1997).
50. Boursnell ME, Entwisle C, Blakeley D et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis. 175(1), 16-25 (1997). (Pubitemid 27020819)
51. Koelle DM. Vaccines for herpes simplex virus infections. Curr. Opin. Investig. Drugs 7(2), 136-141 (2006).
52. Straus SE, Wald A, Kost RG et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J. Infect. Dis. 176(5), 1129-1134 (1997). (Pubitemid 27460974)
53. Casanova G, Cancela R, Alonzo L et al. A double-blind study of the efficacy and safety of the ICP10qPK vaccine against recurrent genital HSV-2 infections. Cutis 70(4), 235-239 (2002). (Pubitemid 41757449)
54. Schwartz EJ, Bodine EN, Blower S. Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines. Hum. Vaccin. 3(6), 231-238 (2007).
55. Tobian AA, Serwadda D, Quinn TC et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N. Engl. J. Med. 360(13), 1298-1309 (2009).
56. Wald A, Langenberg AG, Krantz E et al. The relationship between condom use and herpes simplex virus acquisition. Ann. Intern. Med. 143(10), 707-713 (2005). (Pubitemid 41692528)
57. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis. 158(3), 602-614 (1988). (Pubitemid 18233664)
58. Cadoz M, Micoud M, Seigneurin JM et al. Phase I trial of R7020: a live attenuated recombinant HSV candidate vaccine. Presented at: 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, CA, USA, 11-14 October 1992.
59. Corey L, Langenberg AG, Ashley R et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282(4), 331-340 (1999). (Pubitemid 29350487)
60. Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-dadjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347(21), 1652-1661 (2002).
61. + T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2(2), 129-143 (2009). • Demonstrates that phosphorylated acyclovir inhibits HIV and suggests that acyclovir may have efficacy in the setting of dual infection with both pathogens.
62. Kozlowski PA, Williams SB, Lynch RM et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol. 169(1), 566-574 (2002).
63. Belyakov IM, Derby MA, Ahlers JD et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl Acad. Sci. USA 95(4), 1709-1714 (1998).
64. Van Damme L, Ramjee G, Alary M et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360(9338), 971-977 (2002). (Pubitemid 35284107)
65. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J. Infect. Dis. 184(4), 418-428 (2001).
66. Galen B, Martin AP, Hazrati E et al. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surogate markers of safety. J. Infect. Dis. 195(9), 1332-1339 (2007). (Pubitemid 46649620)
67. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and in vivo: the story of nonoxynol 9. J. Acquir. Immune Defic. Syndr. 39(1), 1-8 (2005).
68. Cheshenko N, Keller MJ, MasCasullo V et al. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob. Agents Chemother. 48(6), 2025-2036 (2004). (Pubitemid 38691593)
69. Patel S, Hazrati E, Cheshenko N et al. Seminal plasma reduces the effectiveness of topical polyanionic microbicdes. J. Infect. Dis. 196(9), 1394-1402 (2007).
70. Karim SA, Coletti A, Richardson B et al. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009.
71. Skoler-Karpoff S, Ramjee G, Ahmed K et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372(9654), 1977-1987 (2008).
72. Van Damme L, Govinden R, Mirembe FM et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359(5), 463-472 (2008).
73. Bourne N, Stanberry LR, Kern ER, Holan G, Matthews B, Bernstein DI. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob. Agents Chemother. 44(9), 2471-2474 (2000). (Pubitemid 30650897)
74. Gong E, Matthews B, McCarthy T et al. Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res. 68(3), 139-146 (2005). (Pubitemid 41612458)
75. Mesquita PM, Wilson SS, Manlow P et al. Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J. Virol. 82(13), 6576-6584 (2008). (Pubitemid 351875134)
76. Madan RP, Mesquita PM, Cheshenko N et al. Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J. Virol. 81(14), 7636-7646 (2007). (Pubitemid 47047849)
77. Guzman EM, Cheshenko N, Shende V et al. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Antivir. Ther. (Lond.) 12(8), 1147-1156 (2007).
78. Tao J, Hu Q, Yang J et al. In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate. Antiviral Res. 75(3), 227-233 (2007). (Pubitemid 46901083)
79. Tuyama AC, Cheshenko N, Carlucci MJ et al. ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. J. Infect. Dis. 194(6), 795-803 (2006). • Representative of the preclinical in vitro and murine model evaluation of the safety and efficacy of a candidate microbicide. (Pubitemid 44344127)
80. Garg S, Anderson RA, Chany CJ 2nd et al. Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception 64(1), 67-75 (2001). (Pubitemid 32787100)
81. John M, Keller MJ, Fam EH et al. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J. Infect. Dis. 192(10), 1731-1740 (2005). (Pubitemid 41587823)
82. Hazrati E, Galen B, Lu W et al. Human a- and b-defensins block multiple steps in herpes simplex virus infection. J. Immunol. 177(12), 8658-8666 (2006). (Pubitemid 44893830)
83. Valore EV, Park CH, Igreti SL, Ganz T. Antimicrobial components of vaginal fluid. Am. J. Obstet. Gynecol. 187(3), 561-568 (2002).
84. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J. Immunol. 175(11), 7560-7567 (2005). (Pubitemid 41713455)
85. Lehrer RI. Primate defensins. Nat. Rev. 2(9), 727-738 (2004).
86. Yasin B, Wang W, Pang M et al. q defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J. Virol. 78(10), 5147-5156 (2004). (Pubitemid 38581467)
87. Brandt CR, Akkarawongsa R, Altmann S et al. Evaluation of a q-defensin in a murine model of herpes simplex virus type 1 keratitis. Invest. Ophthalmol. Vis. Sci. 48(11), 5118-5124 (2007). (Pubitemid 351260922)
88. Galen B, Cheshenko N, Tuyama A, Ramratnam B, Herold BC. Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells. J. Virol. 80(24), 12209-12218 (2006). (Pubitemid 44904371)
89. Wu Y, Navarro F, Lal A et al. Durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe 5(1), 84-94 (2009).
90. Palliser D, Chowdhury D, Wang QY et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439(7072), 89-94 (2006). (Pubitemid 43053634)